Shots:
- LEO Pharma presented data from the P-III (DELTA TEEN) study, showing delgocitinib cream efficacy vs. cream vehicle in adolescents (12–17yrs.) with moderate to severe CHE; 63.5% achieved IGA-CHE treatment success vs. 29.2% with vehicle
- Delgocitinib cream also showed an edge across key 2EPs, including a ≥90% improvement (HECSI-90: 71.6% vs. 37.5%; HESD itch: 64.8% vs. 36.8%), from baseline to 16wks. and was well tolerated
- A pooled analysis of five Phase IIb & III studies confirmed a consistent safety profile up to 52wks. in adults. These findings were presented at EADV’25
Ref: Leo Pharma | Image: Leo Pharma| Press Release
Related News:- LEO Pharma’s Anzupgo (Delgocitinib) Gains the US FDA’s Approval to Treat Chronic Hand Eczema (CHE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
